
Immunome, Inc. (NASDAQ:IMNM – Free Report) – Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Immunome in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($2.64) for the year, down from their prior estimate of ($2.45). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Immunome’s Q4 2026 earnings at ($0.76) EPS, FY2027 earnings at ($2.71) EPS, FY2028 earnings at ($2.41) EPS, FY2029 earnings at ($1.63) EPS and FY2030 earnings at ($0.42) EPS.
A number of other equities research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Immunome from a “sell” rating to a “strong sell” rating in a report on Sunday, October 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Thursday, October 15th. Stifel Nicolaus reduced their price objective on shares of Immunome from $24.00 to $23.00 and set a “hold” rating on the stock in a research note on Tuesday. William Blair started coverage on shares of Immunome in a research report on Friday, October 16th. They set an “outperform” rating on the stock. Finally, Truist Financial raised their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.85.
Immunome Price Performance
Immunome stock opened at $18.77 on Thursday. Immunome has a 12-month low of $16.11 and a 12-month high of $30.06. The stock has a market capitalization of $2.22 billion, a P/E ratio of -7.11 and a beta of 2.68. The firm’s 50-day moving average is $20.65 and its two-hundred day moving average is $22.23.
Immunome (NASDAQ:IMNM – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.14).
Institutional Investors Weigh In On Immunome
Several hedge funds have recently modified their holdings of the stock. Allworth Financial LP purchased a new position in Immunome in the second quarter valued at approximately $25,000. Integrated Wealth Concepts LLC purchased a new stake in Immunome during the second quarter worth approximately $27,000. Assetmark Inc. grew its stake in Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after buying an additional 1,442 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Immunome by 0.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock worth $3,997,000 after buying an additional 1,625 shares during the period. Finally, KBC Group NV acquired a new stake in shares of Immunome in the first quarter worth $60,000. 44.58% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Immunome news, insider Jack Higgins sold 13,200 shares of Immunome stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the sale, the insider owned 65,050 shares in the company, valued at $1,647,066. The trade was a 16.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.21% of the stock is owned by company insiders.
Recent Immunome Headlines
Here are a few of the latest headlines about IMNM:
- Neutral Sentiment: A separate article rounded up analysts’ predictions for Immunome’s Q1 earnings; the supplied report did not include specific estimates. Research Analysts Offer Predictions for Immunome Q1 Earnings
- Negative Sentiment: HC Wainwright lowered EPS forecasts for Q4 2026 and FY2026–FY2030. Notably, its FY2030 estimate moved from a profit of $1.08 per share to a loss of $0.42; estimates for FY2027–FY2029 were also cut. The revisions suggest a weaker expected earnings trajectory. HC Wainwright analyst estimates
- Negative Sentiment: Piper Sandler and Stifel Nicolaus also lowered their Immunome price targets, signaling reduced valuation expectations. The supplied reports did not state the revised target amounts. Piper Sandler price target report Stifel Nicolaus report
About Immunome
Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.
Recommended Stories
- Five stocks we like better than Immunome
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
